How do I calculate insulin resistance indices (G/I ratio, QUICKI, HOMA‑IR, HOMA‑%S) using fasting glucose measured in mg/dL and fasting insulin measured in μU/mL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Calculating Insulin Resistance Indices Using mg/dL and μU/mL

To calculate insulin resistance indices using fasting glucose in mg/dL and fasting insulin in μU/mL, apply these formulas directly without unit conversion: HOMA-IR = (glucose × insulin)/405, QUICKI = 1/[log(insulin) + log(glucose)], G/I ratio = glucose/insulin, and HOMA-%S = (20 × insulin)/(glucose - 3.5).

Standard Formulas for mg/dL Units

When using fasting glucose in mg/dL and fasting insulin in μU/mL (which equals mIU/L), the calculations are straightforward:

HOMA-IR (Homeostasis Model Assessment of Insulin Resistance)

  • Formula: HOMA-IR = (Fasting Glucose in mg/dL × Fasting Insulin in μU/mL) / 405
  • Reference range: Normal values <2.0 in adults 1
  • Interpretation: Values ≥2.86 suggest insulin resistance 1
  • This is the most widely validated index with strong correlation to gold-standard clamp studies 2, 3

QUICKI (Quantitative Insulin Sensitivity Check Index)

  • Formula: QUICKI = 1 / [log(Fasting Insulin in μU/mL) + log(Fasting Glucose in mg/dL)]
  • Reference range: Normal values in healthy adults = 0.366 ± 0.029 4
  • Interpretation: Values <0.357 indicate insulin resistance 4
  • Note that logarithms are base 10 (common logarithm) 3

G/I Ratio (Glucose-to-Insulin Ratio)

  • Formula: G/I Ratio = Fasting Glucose in mg/dL / Fasting Insulin in μU/mL
  • Reference range: Values <4.5 suggest insulin resistance in PCOS women 5
  • Interpretation: A cut-off of ≤6 shows 73.3% sensitivity and 74.7% specificity for detecting abnormal glucose tolerance 6

HOMA-%S (Homeostasis Model Assessment of Insulin Sensitivity)

  • Formula: HOMA-%S = (20 × Fasting Insulin in μU/mL) / (Fasting Glucose in mg/dL - 3.5)
  • This represents insulin sensitivity as a percentage of normal
  • Lower values indicate greater insulin resistance

Practical Considerations

Sample requirements: Obtain fasting samples after 8-14 hours of fasting 7. The patient should avoid smoking and remain seated during collection.

Which index to use: HOMA-IR demonstrates the best overall performance for clinical assessment 2, 8. In one comparative study, HOMA-IR identified 69% of PCOS women with insulin resistance, while fasting insulin alone missed 8 subjects with insulin resistance and endocrine abnormalities 2. For metabolic syndrome screening, HOMA-IR combined with triglycerides (HOMA-TG index) shows the highest diagnostic accuracy 8.

Sex differences: Despite statistically significant differences between men and women, sex-specific reference intervals are not clinically necessary—the same reference ranges apply to both sexes 1.

Clinical context matters: QUICKI and G/I ratio show lower diagnostic accuracy for metabolic syndrome compared to HOMA-IR 8. However, the G/I ratio performs well specifically in PCOS populations for detecting abnormal glucose tolerance 6.

Common Pitfalls to Avoid

  • Do not convert units: These formulas are designed for mg/dL and μU/mL directly. Converting to mmol/L requires different divisors (22.5 instead of 405 for HOMA-IR).
  • Insulin assay variability: Establish laboratory-specific reference ranges when possible, as significant interlaboratory variation exists in insulin measurements 4.
  • Timing sensitivity: Ensure true fasting state; postprandial samples invalidate these calculations.
  • Population differences: Reference ranges may vary by ethnicity and age. The G/I ratio cut-off of <4.5 was validated specifically in obese non-Hispanic white PCOS women 5.

Related Questions

How should a fasting insulin test be performed, what are the normal reference ranges, and how should abnormal results be interpreted and managed?
What are the HOMA‑IR (Homeostatic Model Assessment of Insulin Resistance) cut‑off values for normal insulin sensitivity, mild insulin resistance, significant insulin resistance, and severe insulin resistance, and how should they be interpreted?
When should HOMA‑IR (Homeostatic Model Assessment of Insulin Resistance) be used instead of HbA1c (glycated hemoglobin) for diagnosing, screening, or monitoring diabetes?
How do you calculate the insulin sensitivity factor?
What is the clinical use of the SPISE (Stumvoll Protocol for Insulin Sensitivity Estimation) index for assessing insulin sensitivity?
What is the mechanism of action of lanatoside C?
What are the equivalent settings on a VOCSN vhome ventilator (AVAPS ST (Average Volume Assured Pressure Support – Spontaneous/Timed) mode) for a Philips EVO ventilator set to target tidal volume 350 mL, IPAP (Inspiratory Positive Airway Pressure) minimum 18 cmH₂O, IPAP maximum 30 cmH₂O, EPAP (Expiratory Positive Airway Pressure) 8 cmH₂O, backup rate 14 breaths per minute, and inspiratory time 1.4 seconds?
How should lamotrigine be tapered from 400 mg daily in a patient with bipolar type II?
What diagnoses support the use of Abilify (aripiprazole) in pediatric patients?
What are the indications, dosing schedule, contraindications, and side effects of Hylagan (hyaluronic acid) intra‑articular injections for knee osteoarthritis?
What does an isolated positive antinuclear antibody (ANA) test indicate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.